Walker Francesca, Rothacker Julie, Henderson Christine, Nice Edouard C, Catimel Bruno, Zhang Hui-Hua, Scott Andrew M, Bailey Michael F, Orchard Suzanne G, Adams Timothy E, Liu Zhanqi, Garrett Thomas P J, Clayton Andrew H A, Burgess Antony W
Ludwig Institute for Cancer Research Melbourne - Parkville Branch, Australia.
Growth Factors. 2012 Dec;30(6):394-409. doi: 10.3109/08977194.2012.739619. Epub 2012 Nov 20.
The activation of the epidermal growth factor receptor (EGFR) kinase requires ligand binding to the extracellular domain (ECD). Previous reports demonstrate that the EGFR-ECD can be crystallized in two conformations - a tethered monomer or, in the presence of ligand, an untethered back-to-back dimer. We use Biosensor analysis to demonstrate that even in the monomeric state different C-terminal extensions of both truncated (EGFR(1-501))-ECD and full-length EGFR(1-621)-ECD can change the conformation of the ligand-binding site. The binding of a monoclonal antibody mAb806, which recognizes the dimer interface, to the truncated EGFR(1-501)-Fc fusion protein is reduced in the presence of ligand, consistent with a change in conformation. On the cell surface, the presence of erythroblastosis B2 (erbB2) increases the binding of mAb806 to the EGFR. The conformation of the erbB2: EGFR heterodimer interface changes when the cells are treated with epidermal growth factor (EGF). We propose that ligand induces kinase-inactive, pre-formed EGFR dimers and heterodimers to change conformation leading to kinase-active tetramers, where kinase activation occurs via an asymmetric interaction between EGFR dimers.
表皮生长因子受体(EGFR)激酶的激活需要配体与细胞外结构域(ECD)结合。先前的报道表明,EGFR-ECD可以以两种构象结晶——一种是束缚单体,或者在配体存在的情况下,是一种非束缚的背对背二聚体。我们使用生物传感器分析来证明,即使在单体状态下,截短的(EGFR(1-501))-ECD和全长EGFR(1-621)-ECD的不同C末端延伸都可以改变配体结合位点的构象。识别二聚体界面的单克隆抗体mAb806与截短的EGFR(1-501)-Fc融合蛋白的结合在配体存在时减少,这与构象变化一致。在细胞表面,成红细胞增多症B2(erbB2)的存在增加了mAb806与EGFR的结合。当用表皮生长因子(EGF)处理细胞时,erbB2:EGFR异二聚体界面的构象会发生变化。我们提出,配体诱导激酶无活性的、预先形成的EGFR二聚体和异二聚体改变构象,导致激酶活性的四聚体,其中激酶激活通过EGFR二聚体之间的不对称相互作用发生。